1. Scrip
  2. >>Therapy Areas

Cipla-Serum add new rung to relationship

 
• By Anju Ghangurde

This could be read as growing pre-nuptial synergy between Cipla and the Serum Institute of India. Or maybe the duo's next step in their "relationship" is purely an extension of a previous alliance and one which will see Cipla step up its indirect interest in vaccines play to the Indian market.

This could be read as growing pre-nuptial synergy between Cipla and the Serum Institute of India. Or maybe the duo's next step in their "relationship" is purely an extension of a previous alliance and one which will see Cipla step up its indirect interest in vaccines play to the Indian market.

Cipla, announced on 27 May that it had signed a pact to exclusively market Serum's flu vaccine Nasovac-S in India

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.